|1.||Singer, Daniel E: 12 articles (01/2015 - 11/2003)|
|2.||Go, Alan S: 9 articles (01/2015 - 11/2003)|
|3.||Chang, Yuchiao: 9 articles (01/2015 - 11/2003)|
|4.||Zaidat, Osama O: 8 articles (11/2015 - 02/2002)|
|5.||Nakagawara, Jyoji: 8 articles (09/2015 - 03/2010)|
|6.||Lip, Gregory Y H: 8 articles (08/2015 - 03/2011)|
|7.||Toyoda, Kazunori: 8 articles (08/2015 - 01/2004)|
|8.||Fang, Margaret C: 8 articles (01/2015 - 11/2004)|
|9.||Hopkins, L Nelson: 8 articles (06/2014 - 03/2002)|
|10.||Demchuk, Andrew M: 7 articles (11/2015 - 11/2008)|
|1.||Warfarin (Coumadin)FDA LinkGeneric
12/01/2002 - "This agent is safe and effective; and should be considered for reversal of Warfarin-induced coagulopathy in cases of intracranial hemorrhage, especially when urgent surgical intervention is required."
01/13/2015 - "These associations were most pronounced in patients treated with dabigatran 150 mg twice daily, whereas the association of 75 mg twice daily with study outcomes was indistinguishable from warfarin except for a lower risk of intracranial hemorrhage with dabigatran."
01/01/2015 - "Randomized controlled trials of NOACs have revealed that intracranial hemorrhage (ICH) occurs less frequently with NOACs compared with warfarin. "
05/01/2013 - "A landmark trial shows that the rate of intracranial hemorrhage with dabigatran is lower in this population compared to warfarin. "
04/01/2013 - "In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. "
|2.||Tissue Plasminogen Activator (Alteplase)FDA Link
05/01/2012 - "By using the control groups of intravenous alteplase-treated patients in 8 studies, bridging therapy was associated with a favorable outcome (OR, 2.26; 95% CI, 1.16-4.40), but no differences in mortality or symptomatic intracranial hemorrhage outcomes were found. "
01/01/2010 - "The purpose of this study was to determine the incidence and clinical correlation of intracranial hemorrhages (ICHs) detected by 3-tesla gradient echo T(2)*-weighted images after intravenous recombinant tissue plasminogen activator (rt-PA) administration. "
06/01/2002 - "Postmarketing data suggest that the risk of intracranial hemorrhage may be unacceptably high when recombinant tissue-type plasminogen activator is given to patients who would not have been eligible for enrollment in the pivotal phase 3 clinical trials. "
06/01/2015 - "Intravenous tissue plasminogen activator had been used in 78% of symptomatic intracranial hemorrhage subjects - no higher than in the overall cohort. "
03/01/2015 - "Treatment with recombinant tissue-type plasminogen activator increased the odds of symptomatic intracranial hemorrhage by a greater amount in patients taking prior antiplatelets than those who were not (P=0.019 for test of interaction), but had no clear detrimental effect on functional outcome at 6 months in this group (P=0.781 for test of interaction). "
|3.||recombinant FVIIa (rFVIIa)IBA
04/19/2011 - "For intracranial hemorrhage, mortality was not improved with rFVIIa use across a range of doses. "
01/01/2014 - "Recombinant factor VIIa use in patients presenting with intracranial hemorrhage."
11/01/2006 - "Recombinant factor VIIa for rapid reversal of anticoagulant effect in patients with intracranial hemorrhage: the Israeli experience and review of the literature."
06/01/2003 - "Acute intracranial hemorrhage in a cirrhotic controlled with recombinant factor VIIa."
03/01/1998 - "rFVIIa effectively controlled intracranial hemorrhage in 10 of the 12 patients. "
|4.||Heparin (Liquaemin)FDA LinkGeneric
01/01/1992 - "The patients with intracranial hemorrhages had a significantly greater number of changes in the rate of heparin infusion than matched controls. "
02/01/1989 - "The only intracranial hemorrhage in the trial occurred in a patient initially treated without heparin. "
10/01/2014 - "None of the patients, whether receiving heparin or ASA, had intracranial hemorrhage. "
10/01/2013 - "The use of heparin after initiation of our protocol among operative TBI cases without intracranial hemorrhage (ICH) based on admission head computed tomography was 58 per cent. "
09/01/2011 - "Unfractionated heparin is moderately effective but carries a small risk of intracranial hemorrhage. "
05/01/2015 - "The safety profile is similar to standard anticoagulants, with significant reduction observed in intracranial hemorrhage. "
12/01/2013 - "Randomized studies have shown a decreased risk of intracranial hemorrhage (ICH) with use of novel oral anticoagulants (NOACs). "
11/01/2011 - "However, a recent study showed increased risk of symptomatic intracranial hemorrhage after IV tPA use in patients with oral anticoagulants (OAC) even with an INR less than 1.7. "
11/01/2015 - "At present, the main challenge when prescribing anticoagulants in HGG patients is to address the risk of intracranial hemorrhage and provide the optimal treatment. "
06/01/2015 - "Intracranial hemorrhage (ICH) is one of the most serious and lethal complications of anticoagulants with a reported incidence of 5-18.5 %. "
06/01/2015 - "Further studies are needed, but this approach seems to be suitable for the emergency management of apixaban-associated intracranial hemorrhage."
01/01/2012 - "Upon one-way sensitivity analysis, these results were sensitive to variability in the drug cost of apixaban and various intracranial hemorrhage related variables. "
12/01/2014 - "The differences between dabigatran and apixaban were modest but consistent in sensitivity analyses, with the directionality only changing at the limits of the CIs for the relative risks of ischemic stroke or intracranial hemorrhage or when assuming that both treatment discontinuation and post-event disability rates differ by drug. "
12/10/2013 - "The effect of apixaban on reducing major bleeding and intracranial hemorrhage was consistent in patients with and without CAD. "
11/01/2014 - "Apixaban, a new oral anticoagulant, has been proven to be as safe and effective as traditional anticoagulants while carrying significantly less risk of intracranial hemorrhage. "
03/01/1994 - "Pooled data from large clinical trials suggest that streptokinase has a 0.07% nonfatal intracranial hemorrhage rate. "
01/01/2005 - "In our report, we describe the successful surgical management of a streptokinase-induced intracranial hemorrhage. "
01/01/2005 - "In our report, we describe the successful surgical management of a streptokinase-induced intracranial hemorrhage. "
08/01/2002 - "Including the risk of intracranial hemorrhage, our model predicted that treating half the GUSTO patients with tPA and the others with streptokinase would yield similar outcomes as treating all patients with tPA, because the additional risk of intracranial hemorrhage exceeded the expected benefit in some patients. "
03/01/1994 - "If a new thrombolytic regimen provides a 1% absolute reduction in early mortality compared with streptokinase therapy, approximately a > or = 3.2% nonfatal intracranial hemorrhage rate is justified to obtain this survival benefit. "
10/01/1994 - "In preliminary studies antenatal intravenous gamma globulin therapy has shown promise in preventing the development of intracranial hemorrhage and ameliorating fetal thrombocytopenia. "
07/01/1992 - "Antenatal treatment of alloimmune thrombocytopenia with weekly gamma globulin effectively improves the fetal platelet count and prevents intracranial hemorrhage."
11/24/1988 - "We conclude that intravenous gamma globulin, with or without dexamethasone, is effective in elevating the fetal platelet count in severe cases of neonatal alloimmune thrombocytopenia and in helping to avoid intracranial hemorrhage."
01/01/1992 - "Early diagnosis allows an appropriate management: fetal blood sampling as early as 20 weeks of gestation; in case of fetal thrombocytopenia, treatment by intravenous gamma globulin (1.0 g/kg/b.w.) each week during 8 weeks or more; ultrasound screening of in utero hemorrhage, particularly intracranial hemorrhage; fetal blood sampling before delivery at term and in utero transfusion of platelet antigen negative in case of persistence of fetal thrombocytopenia."
05/01/1996 - "Our purposes were to investigate maternal infusions of intravenous gamma-globulin, to prevent intracranial hemorrhage, and to determine whether 1.5 mg dexamethasone and 60 mg prednisone per day add to the effect of intravenous gamma-globulin. "
11/01/2014 - "Thus, rt-PA therapy in combination with edaravone improved the recanalization rate, reduced the incidence of intracranial hemorrhage, and improved functional prognosis."
02/01/2009 - "We examined the mechanisms by which edaravone may help to suppress rtPA-induced brain hemorrhage. "
02/01/2009 - "Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator."
|10.||Vitamin KFDA Link
09/01/2014 - "Studies of efficacy and safety prior to the marketing of these molecules showed a decreased risk of intracranial hemorrhage compared with vitamin K antagonists. "
01/01/1989 - "In order to evaluate the effect of vitamin K prophylaxis on the incidence of intracranial hemorrhage (ICH) in infants aged from 1 week to 12 months, a prospective surveillance study, from 1974 to 1988, was performed on the well-defined population of Nagasaki Prefecture, Japan. "
01/01/1989 - "Incidence and causes of intracranial hemorrhage in infancy: a prospective surveillance study after vitamin K prophylaxis."
10/01/2015 - "We hypothesized that a policy of prophylactic fresh frozen plasma (FFP) infusion in patients having falls would reverse vitamin K antagonists (VKAs) and that reversal would decrease delayed intracranial hemorrhage (ICH). "
01/01/2015 - "Characteristics of Symptomatic Intracranial Hemorrhage in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulant Therapy."
|1.||Drug Therapy (Chemotherapy)
09/01/2010 - "Despite salvage chemotherapy, he died of brain hemorrhage twenty-four months after complete remission."
01/01/2008 - "Also, brain hemorrhages that could result from chemotherapy effects on the hemostatic system were reported. "
01/01/1991 - "Two of the 12 patients with VAHS died of an intracranial hemorrhage and 7 of the 14 patients with MH died despite chemotherapy. "
04/01/1995 - "In children with central nervous system neoplasia who have undergone cranial irradiation, or radiation combined with chemotherapy, delayed intracranial hemorrhage may develop."
04/01/1995 - "We retrospectively analyzed the medical records and imaging examinations of 20 pediatric patients (ages 1 to 15 years) with intracranial neoplasia in whom delayed intracranial hemorrhage developed after cranial irradiation or radiation combined with systemic or intrathecal chemotherapy. "
06/01/2009 - "On clinical follow-up (mean 12.6 months, range 1-27 months), two patients with intracranial hemorrhage and one patient with cerebellar symptoms improved significantly after treatment, with residual symptoms that did not affect independence. "
11/01/1990 - "It is concluded that treatment with the single-dose surfactant regimen used in this study reduces the severity of respiratory distress during the 48 hours after treatment and decreases the major pulmonary morbidity and intracranial hemorrhage in premature neonates with RDS. "
01/01/2016 - "Two patients had brain hemorrhages after treatment. "
03/01/2015 - "During follow-up, 12 events of intracranial hemorrhage after treatment were identified. "
12/01/2012 - "The safety outcome was symptomatic intracranial hemorrhage within 48 hours after treatment. "
01/01/2005 - "We propose that inclusion of such patients in trials assessing safety/efficacy of thrombolytic therapy in the treatment of patients with intracranial hemorrhage should be carefully considered."
09/01/2015 - "A descriptive review of included studies also supports these findings, and in addition, it suggests that systolic BPV may be associated with increased risk of intracranial hemorrhage in those treated with thrombolytic therapy. "
09/01/2014 - "Recent clinical trials demonstrated the hemodynamic benefit of IV thrombolytic therapy among these patients; however, it came at the cost of a significantly increased risk of major, particularly intracranial, hemorrhage. "
01/24/2001 - "Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy."
02/01/1994 - "The results of randomized trials will be important in clarifying any cause-effect relationships between thrombolytic therapy and symptomatic and asymptomatic intracranial hemorrhage. "
12/01/2015 - "Determinants of Intracranial Hemorrhage Occurrence and Outcome after Neurothrombectomy Therapy: Insights from the Solitaire FR With Intention For Thrombectomy Randomized Trial."
03/01/2009 - "Clinical outcomes of an open-label study of mechanical thrombectomy were compared with a hypothetical control group with a lower recanalization rate (18 vs 60%) and a lower rate of symptomatic intracranial hemorrhage (0.6 vs 7.8%) than the active treatment group. "
12/01/2015 - "It is not associated with a significantly higher risk of symptomatic intracranial hemorrhage compared with published series for mechanical thrombectomy alone."
11/03/2015 - "Compared with standard medical care, endovascular thrombectomy was associated with significantly higher rates of angiographic revascularization at 24 hours (75.8% vs 34.1%; OR, 6.49; 95% CI, 4.79-8.79; P < .001) but no significant difference in rates of symptomatic intracranial hemorrhage within 90 days (70 events [5.7%] vs 53 events [5.1%]; OR, 1.12; 95% CI, 0.77-1.63; P = .56) or all-cause mortality at 90 days (218 deaths [15.8%] vs 201 deaths [17.8%]; OR, 0.87; 95% CI, 0.68-1.12; P = .27). "
06/11/2015 - "At 90 days, the rates of symptomatic intracranial hemorrhage were 1.9% in both the thrombectomy group and the control group (P=1.00), and rates of death were 18.4% and 15.5%, respectively (P=0.60). "
|5.||Platelet Transfusion (Blood Platelet Transfusions)
07/01/2009 - "There was no side-effect except for slight marrow suppression in 3 patients and one patient died from brain hemorrhage on inefficacy of platelet transfusion. "
02/01/2002 - "Early diagnosis and appropriate platelet transfusion therapy are essential to prevent life-threatening intracranial hemorrhage in the thrombocytopenic fetus or neonate. "
01/01/2001 - "We observed one early death in a platelet transfusion refractory blastic phase CML patient due to intracranial hemorrhage. "
08/01/2011 - "To determine whether there is a benefit to platelet transfusion in mild traumatic brain injury (MTBI) patients with intracranial hemorrhage (ICH), taking antiplatelet therapy before hospitalization. "
09/01/1990 - "One patients (case 4, 31-y-o female) died of brain hemorrhage due to the thrombocytopenia refractory to platelet transfusion because of anti-platelet antibody in 34 days after BMT. "